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Abstract
Background: Genome-wide gene expression profile using deep sequencing technologies can drive the discovery of cancer
biomarkers and therapeutic targets. Such efforts are often limited to profiling the expression signature of either mRNA or
microRNA (miRNA) in a single type of cancer.
Methodology: Here we provided an integrated analysis of the genome-wide mRNA and miRNA expression profiles of three
different genitourinary cancers: carcinomas of the bladder, kidney and testis.
Principal Findings: Our results highlight the general or cancer-specific roles of several genes and miRNAs that may serve as
candidate oncogenes or suppressors of tumor development. Further comparative analyses at the systems level revealed
that significant aberrations of the cell adhesion process, p53 signaling, calcium signaling, the ECM-receptor and cell cycle
pathways, the DNA repair and replication processes and the immune and inflammatory response processes were the
common hallmarks of human cancers. Gene sets showing testicular cancer-specific deregulation patterns were mainly
implicated in processes related to male reproductive function, and general disruptions of multiple metabolic pathways and
processes related to cell migration were the characteristic molecular events for renal and bladder cancer, respectively.
Furthermore, we also demonstrated that tumors with the same histological origins and genes with similar functions tended
to group together in a clustering analysis. By assessing the correlation between the expression of each miRNA and its
targets, we determined that deregulation of ‘key’ miRNAs may result in the global aberration of one or more pathways or
processes as a whole.
Conclusions: This systematic analysis deciphered the molecular phenotypes of three genitourinary cancers and investigated
their variations at the miRNA level simultaneously. Our results provided a valuable source for future studies and highlighted
some promising genes, miRNAs, pathways and processes that may be useful for diagnostic or therapeutic applications.
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Introduction
Genitourinary neoplasms pose a large burden on human
healthcare, with prostatic carcinoma ranked as the most
predominant genitourinary tumors followed by bladder and
kidney carcinoma in America [1], other types of genitourinary
tumors are relatively uncommon. However, bladder, kidney,
prostate and testicular carcinoma are the top four genitourinary
tumors in China [2]. Bladder cancer is one of the most expensive
cancers due to the necessity of life-long surveillance involving
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22570upper tract imaging, urinary cytology, and cystoscopy from
diagnosis until the death of the patient [3]. Renal cell carcinoma
(RCC) accounts for approximately 2% of all cancers, with a
worldwide annual increase of 1.5–5.9% [4,5]. Testicular cancer,
on the other hand, represents between 1% and 1.5% of male
neoplasms and 5% of urological tumors in general, and it is the
most common cancer diagnosis in men between the age of 15 to
35 [6,7]. Furthermore, epidemiological surveys indicate that there
is a clear trend toward an increasing incidence of testicular cancer
in most industrialized countries in North America, Europe and
Oceania in recent decades, although substantial differences in the
incidence rates are observed between neighboring countries [8].
Despite intensive efforts by many investigators over the past
years, the exact mechanisms involved in the initiation and
progression of these genitourinary cancers remain largely unclear.
Transitional cell carcinoma (TCC) of the bladder is the most
common (,90%) histopathological type of bladder cancer. Many
factors, including chromosomal anomalies, genetic polymor-
phisms, and genetic and epigenetic alterations, are thought to
contribute to the tumorigenesis or progression of TCC [9].
Similarly, multiple environmental and genetic factors are also
proposed to be associated with the development of clear cell renal
cell carcinoma (ccRCC), which is the most common subtype
(,70%) of renal cell carcinoma [10]. In the case of testicular germ
cell tumors (TGCT), the predominant (90–95%) subtype of
testicular cancer, previous genome-wide expression analysis or
targeted studies investigated the alpha-fetoprotein (AFP) mRNA
level in atypical seminomas showed that seminomas and
embryonal carcinomas may develop through common molecular
mechanisms [11].
Our previous work on ccRCC demonstrated that simultaneously
profiling the expression patterns of mRNAs and miRNAs in the
same panel of cancer patients using a massively parallel sequencing
platform (Illumina GA II) is a highly integrative and reproducible
way of dissecting the molecular basis of human cancer [12]. Here
we first generated the whole-genome expression profiles of protein
coding genes in TCC and TGCT and characterized the expression
patterns of miRNAs in TGCT. Combined with the results of our
previous studies on ccRCC [12] and TCC [13], systematic
comparison of the three different genitourinary cancers at both
mRNA and miRNA levels in a total of 27 patient-matched tumor-
normal tissue pairs identified multiple genes and miRNAs that were
uniformly deregulated in all three genitourinary cancers or solely
deregulated in a single kind of cancer. In addition, system-level or
pathway-based analysis also highlighted the roles of common
alterations inseveralcancerpathways and cancer-specificmolecular
events in tumor development.
Results
A snapshot of mRNA and miRNA profiling results
generated in TGCT, TCC and ccRCC
Large numbers of transcripts showed consistent patterns of
expression among the patients (seven TGCTs, ten TCCs and ten
ccRCCs) with the same genitourinary cancer. Compared to the
matched normal control, a total of 3181, 4321 and 4596 mRNAs
were significantly differentially expressed (absolute value of log2
ratio $1, FDR#0.01) in TGCT, TCC and ccRCC, respectively.
The numbers of miRNAs significantly deregulated in those three
cancers were 254, 226 and 118, respectively (absolute value of log2
ratio $1, P#0.01). Statistical methods for determining the
differentially expressed genes and miRNAs are described previ-
ously [12], and full lists of deregulated mRNAs and miRNAs can
be found in Table S1 and S2, respectively. As reported in our
previous studies [12,13], the results of our whole-genome
expression analysis correlated well with independent qPCR
validation results, which is indicative of the good reliability of
our sequencing approach and analytical pipeline.
As shown in Figure 1, there were 103 and 185 genes that were
detected to be up-regulated or down-regulated consistently in all of
the three cancers, respectively, and only nine and eight miRNAs
displayed consistent up- and down-regulation patterns, respective-
ly. The numbers of genes and miRNAs that were deregulated (up
or down) only in TGCT were 1,819 (527 up-regulated and 1,292
down-regulated) and 150, respectively. We also observed 2,697
genes and 124 miRNAs exhibiting significant expression changes
only in TCC, and 3,182 genes and 69 miRNAs were deregulated
solely in ccRCC. The remaining numbers in Figure 1 represent
genes and miRNAs that were uniformly deregulated in two of the
three genitourinary cancers.
Pathway enrichment of genes significantly deregulated
in the three cancers
All of the genes that were deregulated in each of the three
cancers were used as inputs for the DAVID bioinformatics
resource separately to identify the significantly deregulated
pathways [14]. The resulting lists of KEGG pathways signifi-
cantly enriched (P#0.05) in deregulated genes in TGCT, TCC
and ccRCC are listed in Table S3. As illustrated in Figure 2, the
cell adhesion molecules (CAMs) pathway was affected in all the
three cancers. Other pathways disrupted in two cancers
included p53 signaling and the ECM-receptor and cell cycle
pathways, which were disrupted in TCC and ccRCC, and the
calcium signaling pathway, which was disrupted in TCC and
TGCT. The cytokine-cytokine receptor interaction pathway
was affected in both TGCT and ccRCC. Notably, the
chemokine signaling pathway was also significantly enriched in
deregulated genes in TCC, which indicated that perturbation of
the normal function of cytokines might be a common molecular
event in tumor development [15]. Other pathways that were
a f f e c t e do n l yi nas i n g l et y p eo fc a n c e r( f o ri n s t a n c e ,M A P K
signaling in TCC and glycolysis in ccRCC) are also illustrated in
Figure 2. Interestingly, as noted in previous studies, global
down-regulation of multiple metabolic pathways might be a
characteristic phenotype of ccRC C ,a tl e a s ti nc o m p a r i s o nw i t h
the other two cancers profiled.
Gene Ontology (GO) enrichment analysis of genes
differentially expressed in the three cancers
Gene sets showing the same deregulated expression patterns in
multiple cancers or genes showing cancer-specific expression
deregulation are thought to be functionally important to the
tumorigenic processes [16]. Thus, we examined all genes that
exhibited the same deregulation patterns in two or three
genitourinary cancers and all genes that were solely deregulated
in only one cancer against the GO database to identify the
significantly deregulated GO biological process terms (adjusted
P#0.05). The detailed results of the GO enrichment analysis are
listed in Table S4. For the 288 genes that displayed the same
deregulation patterns in all the three cancers, most of the
extremely enriched GO biological terms were related to the cell
cycle process (adjusted P#5.0610
-05). Other important biological
processes that were significantly enriched in genes deregulated in
any two of the three cancers included the developmental process,
cell adhesion and the cell differentiation process, which were
affected in TGCT and TCC; the immune and inflammatory
response process, which was affected in TGCT and ccRCC; and
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TCC and ccRCC. Remarkably, we also observed that gene sets
showing TGCT-specific deregulation patterns were mainly impli-
cated in processes related to male reproductive function, such as
spermatogenesis, fertilization and spermatid development [17].
Genes solely deregulated in TCC were enriched in biological
processes associated with tumor invasiveness and metastasis, such as
the developmental process, cell (-matrix) adhesion, cell differenti-
ation, cell motion and cell junction organization [18]. Many genes
that were deregulated only in ccRCC were implicated in processes
associated with the immune response and transmembrane transport
of relatively small molecules.
Gene Expression Correlates with Tumor Types
We next studied the differences in gene expression profiles that
could be used to distinguish between, or give biological insights
into the molecular disparities of the tumors with distinct
histological origins. Of the 596 genes that were deregulated in
all the three cancers (Table S5), 64 were differentially expressed
(absolute value of log2 ratio $1, FDR #0.01) in at least 75% of the
27 patients. As shown in Figure 3, unsupervised hierarchical
clustering of the tumor samples based on the relative expression
levels of these 64 genes revealed that tumors with the same
histological origin generally tended to group together (except
TGCT T17 and T18) and that these genes could be divided into
five major clusters showing different expression patterns among
the tumors. Genes in cluster 1 and cluster 2 were predominantly
up-regulated and down-regulated in the majority of tumors
sequenced, respectively. In contrast, genes grouped in cluster 3
were up-regulated in ccRCC but down-expressed in TCC and
TGCT.
Deregulated expression patterns of miRNAs in the three
genitourinary cancers
In this comparative study, we observed that over half (17/31) of
the miRNAs that were aberrantly expressed in all the three
cancers exhibited consistent expression patterns (Figure 1C and
1D). Many of these miRNAs (such as miR-142-3p, miR-155, miR-
21 and miR-210) that were known to function as ‘oncogenes’ in
previous studies were observed to be uniformly up-regulated, while
other potential ‘tumor suppressors’ such as let-7c and miR-214
were down-regulated in our study (reviewed by Ramiro Garzon et
al. [19] and Aurora Esquela-Kerscher et al. [20]). A large
proportion of the deregulated miRNAs also showed cancer-
specific expression patterns (Figure 1C and 1D). Consistent with
other studies on TGCT [21,22], miR-372 and miR-373 have been
suggested to act as oncogenes, and were found to be up-regulated
solely in TGCT as well as the star form miR-373* in our study,
further confirming their special roles in TGCT development.
miRNAs solely deregulated in the other two cancers included
miR-143 and miR-195, which were down-regulated in TCC.
miR-122, a previously recognized tumor suppressor that had been
shown to be specific to liver cancer [23], was up-regulated in
ccRCC.
As shown in Table 1, we also noticed that a significant number
of miRNA families were deregulated in two or three types of
cancers. Multiple members of the miR-8 family, whose associa-
tions with human cancers had been reported repeatedly [24,25],
exhibited varied expression patterns in these three cancers. Other
miRNA families (such as the miR-199, miR-17 and miR-506
families) that have not received previous annotation in cancer
studies were also observed to be deregulated either consistently or
inconsistently in two or three tumor types in this study (Table 1).
Figure 1. Deregulated genes and miRNAs in TCC, TGCT and ccRCC. Venn diagrams illustrate the overlapping relationship of the number of
up-regulated genes (A), down-regulated genes (B), up-regulated miRNAs (C) and down-regulated miRNAs (D) among these cancers.
doi:10.1371/journal.pone.0022570.g001
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clusters that exhibited TGCT-specific up-regulated expression
patterns (Table S2). 42 members of the miR-515 family (miR-515–
527) and eight members of the miR-302–367 cluster (miR-302a,
miR-302a*, miR-302b, miR-302b* miR-302c, miR-302d, miR-
302d* and miR-367) were only up-regulated in TGCT and not in
the other two cancers, and three members of the miR-105-767
cluster (miR-105, miR-105* and miR-767-5p) were ranked as the
top ten up-regulated miRNAs in TGCT.
Pearson’s correlation between the expression levels of
differentially expressed miRNAs and their potential target
genes
We then investigated the biological relevance of the significantly
deregulated miRNAs by evaluating the correlation between the
expression levels of each miRNA and all of its predicted target
genes. Significant correlations (P#0.05) were found between 77,
196 and 444 miRNA-mRNA pairs in TGCT, TCC and ccRCC,
respectively (Table S6). The GO biological processes that were
enriched with these significantly correlated target genes were
determined using DAVID, and the enriched GO categories are
listed in Table S7 for TGCT, TCC and ccRCC, respectively.
Multiple core regulatory processes or signaling pathways that are
likely to be of functional relevance to tumor development,
including the developmental process, the JAK-STAT cascade,
cell differentiation, cell motion and other processes associated with
cell death or apoptosis regulation, were all predicted to be under
the potential influence of deregulated miRNAs.
By careful examination of the individual miRNAs that
negatively correlated with the expression levels of their target
genes, we found that miR-367 (belonging to the miR-302-367
cluster mentioned above) was up-regulated solely in TGCT and its
predicted target CDKN1C, an imprinted gene which is character-
ized by frequent loss of imprinting in esophageal and breast
cancers, was also down-regulated in TGCT (r=-0.59, P=0.024)
[26,27]. Another miRNA, miR-195, was down-regulated and its
target MAP7, which is predominantly expressed in cells of
epithelial origin and is able to stabilize microtubules, was observed
to be up-regulated in TCC (r=20.48, P=0.031) [28].
As expected, the expression levels of some miRNAs were
significantly correlated with multiple target genes. 43 predicted
target genes under the regulation of the up-regulated miR-19a/b
were all down-regulated in TCC, and 11 of them were predicted
Figure 2. KEGG pathways significantly enriched with differentially expressed genes in TCC, TGCT and ccRCC. KEGG pathways
significantly enriched (P#0.05) with differentially expressed genes are illustrated, and the human disease pathways are manually removed. Pathways
that were significantly enriched in all of three cancers are depicted in red, those enriched in two cancers are in yellow, and those enriched in only one
cancer are in green.
doi:10.1371/journal.pone.0022570.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22570Figure 3. Unsupervised hierarchical clustering of expression data from 64 genes. The differential expression value matrix of 64 genes with
absolute value of log2 ratio $1 and FDR#0.01 in at least 75% of 27 patients was used to perform unsupervised hierarchical clustering. The different
tumor types (labeled in top; B, TCC; T, TGCT; K, ccRCC) were clustered by the up-regulation (red) and down-regulation (green) patterns of
corresponding genes (listed vertically by their official gene symbol).
doi:10.1371/journal.pone.0022570.g003
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addition, three miRNAs miR-20b, miR-363 and miR-30c that
were all solely down-regulated in ccRCC also showed significant
correlation with the expression levels of 23, 25 and 37 of their
predicted target genes, respectively (Table S6). Notably, the
correlated target genes of miR-20b were mainly implicated in the
regulation of metabolic processes (adjusted P=0.037) and three of
the targets (JAK1, CCND2 and SPRED1) participate in regulating
the JAK-STAT signaling pathway. However, no enriched
biological process was found in the correlated target gene sets of
miR-30c and miR-363.
Discussion
The present study provided an integrated overview of three
genitourinary cancers based on their whole-genome expression
profiles of both mRNA and miRNA. All matched tumor-normal
sample pairs from the 27 cancer patients were prepared and
sequenced using the same protocols on the same platform, and the
resulting raw sequencing data were also submitted to similar
preliminary analyses [12]. Thus, we assumed that technical
variations due to inter-laboratory or inter-platform differences
should be minimal or negligible in this study. Our results revealed
that the comparative analysis of different cancers could provide
additional in-depth insights into the system-level molecular
mechanisms of tumorigenesis that are otherwise relatively difficult
to be deciphered by focusing on only a single type of cancer.
Furthermore, we obtained the expression profiles of miRNAs and
protein-coding genes in all 27 patients. Integrative analysis of
mRNA and miRNA expression profiles facilitated the identifica-
tion of deregulated biological processes or pathways that may be
under the regulation of miRNAs, which in turn could serve as
ideal therapeutic targets [29].
Research over recent decades has suggested that transformation
of normal cells into malignant cancers may be governed by several
common rules [30]. Our comparative analysis of the three
different genitourinary cancers also revealed the common
physiological changes occurring in tumor cells. Significant
deregulation of developmental and differentiation processes and
the pathways controlling cell cycle in two or more cancers
indicated that the dedifferentiated tumor cells were insensitive to
the inhibitory (anti-growth) signals that would normally block the
entry into an active cell cycle state. Deregulation of the p53
signaling pathways may facilitate both angiogenesis and resistance
to apoptosis [31]. Aberration of the CAMs pathway and ECM
receptors enables cancer cells to escape their primary tumor
masses, invade adjacent tissues and colonize elsewhere [32,33].
Additionally, as demonstrated in our study, frequent deregulation
of the cytokine-related pathways as well as the immune and
inflammatory response processes is another common hallmark of
human cancer [34]. For many solid tumors, cytokines, together
with CAMs, play important roles in the induction of antitumor
immune responses and tumor rejection in the tumor microenvi-
ronment where immune and malignant cells interact [35].
Moreover, recent emerging data suggested that cancer-related
inflammation contributes to the proliferation and survival of tumor
cells and linked this inflammation to the therapeutic response and
prognosis of cancer patients [36].
Systematic comparisons of three genitourinary cancers also
demonstrated that a large number of deregulated genes were
enriched in specific pathways or processes that characterize the
distinct biological behaviors of each cancer. Gene sets solely
deregulated in TGCT are mainly implicated in male reproduc-
tion-related processes such as spermatogenesis, spermatid devel-
opment and fertilization, indicating that normal testicular function
had been lost during the conversion of normal somatic cells into
tumor cells. Meanwhile, global down-regulation of multiple
metabolic pathways and significant deregulation of biological
processes related to blood coagulation, lipid and ion transport
were only observed in ccRCC. As reported previously, disorder of
intravascular coagulation may result in renal lesions [37]. The
unique expression profile of TCC was characterized by significant
deregulation of processes linked to tumor invasiveness and
metastasis. In accordance with its molecular phenotypes, TCC
also behaves uniquely in terms of its clinical features and
prognosis. It is estimated that approximately 70% of TCC
patients present superficial non-muscle-invasive tumors that are
not life-threatening but tend to recur; the remaining cases
presenting muscle-invasive tumors are usually at a high risk of
death associated with distant metastasis [38].
Classification of cancer based on the expression patterns of key
molecular markers that can be used for cancer diagnosis, prognosis
and prediction had been widely described and applied in previous
studies [39]. In this study, hierarchical clustering of genes
deregulated in the majority (over 75%) of patients profiled can
generally classify the tumors into groups with the same
histopathological manifestations (Figure 3). Genes in cluster 1
are dominated by oncogenes that are up-regulated in most tumors,
such as CCND1, PERP and RRM2 [40,41,42]. Moreover, TCF19
encodes a transcription factor that is assumed to play a pivotal role
in regulating the expression of target genes. The gene product of
CCNB1 (cyclin B1) and cdc2 form the maturation-promoting
complex, which is important for stimulating mitosis [43]. The
Table 1. miRNA families deregulated in TCC, TGCT, ccRCC.
Family
Deregulated
members TCC
a TGCT ccRCC
mir-8 miR-141 3.28 1.98 22.06
miR-200a 3.05 21.22 21.14
miR-200b 2.98 22.39 21.59
miR-200b* 3.20 21.55 21.33
miR-200c 2.97 2.47 23.25
miR-429 3.30 - 21.88
mir-199 miR-199a-3p 21.72 21.20 21.24
miR-199a-5p 21.80 21.26 21.30
miR-199b-3p 21.72 21.20 21.24
mir-17 miR-106b 2.10 1.47 -
miR-106b* 1.09 1.27 -
miR-18a 2.56 1.87 -
miR-18a* 1.34 1.18 -
miR-20a 1.82 1.22 -
miR-20a* 1.12 1.41 -
miR-93 1.94 1.48 -
mir-506 miR-506 - 21.98 23.30
miR-508-3p - 21.21 23.83
miR-509-5p - 21.26 23.65
miR-510 - 21.71 21.51
miR-513c - 21.14 21.40
miR-514 - 21.92 23.63
aLog2 ratio value (tumor versus normal tissue), P#0.01.
doi:10.1371/journal.pone.0022570.t001
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during mitosis [44] and can be used as a valuable marker of
nasopharyngeal carcinoma progression [45]. In contrast, genes
belonging to cluster 2 significantly lost their expression in most of
the genitourinary neoplasms profiled. Many genes grouped in
cluster 2 are recognized as candidate tumor suppressors in
previous studies. Methylation-associated silencing of FAM107A
was identified in the three genitourinary tumors [46]. The protein
product of DCN (decorin) is capable of suppressing the growth of
various tumor cells [47,48,49]. TCF21 was aberrantly methylated
and silenced in head and neck squamous cell carcinoma and non-
small-cell lung cancer [50]; C2orf40 was hypermethylated and
transcriptional silenced in colorectal carcinoma and glioma, and
its over-expression led to a significant decrease in cell growth [51].
Overall, though most of genes mentioned above were well-known
for other cancers, their abnormalities in genitourinary tumors were
seldom reported before. Our findings highlighted their general
effects in TCC, TGCT and ccRCC. Furthermore, as genes with
similar expression patterns or functions tending to group together,
other genes (e.g., TCF19) in cluster 1 and 2 may also be
responsible for important functions in these three cancers and thus
are worthy of further attention in future studies.
In addition, we also identified a subset of genes (cluster 3) that
were up-regulated in ccRCC but down-regulated in TCC and
TGCT. The expression of CNN1 is a late stage differentiation
marker of smooth muscle cells, and a decrease in CNN1 is
associated with underdeveloped renal tumor vessels that lack
integrity [52,53]. Three genes (AMOTL1, CAV1 and COL15A1)i n
this class were functionally associated with the angiogenesis
process. AMOTL1 controls cell migration and cell-cell adhesion
in vivo during angiogenesis [54]. CAV1 enhances the formation of
endothelial capillaries [55] and the silencing of its expression by
antisense oligodeoxynucleotides impairs the angiogenesis process
in vitro and in vivo [56]. Moreover, over-expression of CAV1 in
ccRCC had been documented previously and is thought to be
important for the progression of ccRCC [57,58]. Vascular systems
in different tumors are exceptionally variable in their sizes, shapes
and branching patterns and are usually not organized in the
conventional hierarchy of arterioles, capillaries and venules [59].
Renal cell carcinoma is a vascular-rich tumor, and we envisioned
the possibility that the larger the tumor mass is, the more complex
vascular system the tumor needs for nutrition. Thus, adaptive
over-expression of angiogenesis-related genes should be essential
for the proliferation of tumor cells within the huge mass of ccRCC.
miRNAs are an important class of small non-coding RNAs that
are capable of regulating the temporal and tissue-specific
expression patterns of protein coding genes at the post-transcrip-
tional level, blocking translation and/or leading to mRNA
degradation [60]. miRNAs play active roles in tumorigenesis by
regulating the expression of their target genes, resulting in an
aberration of multiple core biological processes or pathways
[20,61]. Our analysis identified a number of annotated cancer-
associated miRNAs such as miR-142-3p, miR-155, miR-21, miR-
210, let-7c and miR-214 exhibiting consistent deregulation in
TCC, TGCT and ccRCC, which may suggest their general effects
on human cancer development. Some miRNA families or clusters
as a whole were also significantly deregulated in our study
(Table 1). The observed co-expression patterns for these miRNA
families or clusters were expected, as other studies had proposed
that most of the known miRNAs are tandemly clustered and
transcribed as polycistronic primary transcripts [62,63]. miR-8
(also known as ‘‘miR-200’’) family exhibited different patterns in
TCC, TGCT and ccRCC in our study. Down-regulation of miR-
8 family were identified in multiple cancers like breast, ovarian
and pancreatic neuroendocrine tumors, and inhibition of miR-8
family induces the epithelial-to-mesenchymal transition (EMT),
which is viewed as an essential early step in tumor metastasis
[24,25,64]. Interestingly, over-expression of miR-8 family has
been also shown to enhance mouse breast cancer cell colonization
to form distant metastases [65]. In short, miR-8 family may play
different roles in different human cancers, and our data also
suggested their diverse roles in the genitourinary cancers.
Integrative correlation analysis of the expression levels of
miRNAs and their predicted target genes in the three cancers
further highlighted the effects of certain miRNAs on tumor
development. Of the large number of targets whose expression
levels correlated negatively with miR-19a and/or miR-19b in
TCC (Table S6), many genes were well known to be associated
with cancer based on previous functional studies. For instance, the
product of target gene ARRDC3 can bind and degrade the ITGb4
protein, which affects the proliferation, migration and invasion of
breast cancer cells in vitro [66]. The expression of another target,
CBX7, decreases with malignancy grade and neoplasia stage in
thyroid cancer [67] and is associated with a more aggressive
phenotype in pancreatic cancer [68]. Thus, we believed that
down-regulation of miR-19a and miR-19b may also promote the
tumorigenic process of TCC. Another miRNA worthy of notice is
miR-20b in ccRCC, which targeted 3 genes (JAK1, CCND2 and
SPRED1) participating in JAK-STAT signaling. Down-regulation
of miR-20b may therefore lead to the activation of the JAK-STAT
pathway, which has been documented in many cancer studies
[69,70,71,72]. Strikingly, the down-regulated targets of miR-20b
have been mainly implicated in many metabolic processes
(adjusted P=0.037), which may, in part, account for the
characteristic phenotype of ccRCC (global deregulation of
multiple metabolic pathways in ccRCC as shown in Figure 2).
In short, the aberrant expression of miR-19a/b and miR-20b may
result in the alterations of many downstream activities, and they
may therefore they may serve as the ideal candidates for future
therapeutics development.
In summary, we present a comparative analysis of the whole-
genome expression profiles of both mRNA and miRNA in three
different genitourinary cancers, TCC, TGCT and ccRCC. Our
findings reveal the common changes in a few conserved biological
processes or pathways in human cancer and highlight the effects of
several commonly deregulated genes and miRNAs on tumor
development. In addition, our analysis also identified a number of
pathways, processes and individual markers that showed cancer-
specific expression changes. Taken together, this integrated
comparative study generated a system-level sketch of the
molecular phenotypes of TCC, TGCT and ccRCC and
simultaneously investigated the variations of miRNA levels in
the each matched cancer patient. Our study can serve as a
valuable source for future studies on a given cancer or different
carcinomas, and some of the highlighted genes, miRNAs,
pathways or processes may be useful for diagnostic or therapeutic
purposes.
Materials and Methods
Clinical sample collection
Written informed consent from all patients was obtained, and
this series of studies was reviewed and approved by Institutional
Ethics Committees of Peking University Shenzhen Hospital
(Shenzhen, China). All tumor and matched normal adjacent
tissues in this study were obtained from the biobank
(CXC201005260001A) of the Urinogenital Cancer Genomics
Consortium (UCGC) in China. Information on the 27 patients
mRNA and microRNA Profiling of Three Cancers
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22570(10 TCC, 7 TGCT and 10 ccRCC) analyzed is summarized in
Table S8. Specimens were deposited in RNALater (Qiagen,
Germany) or snap-frozen in liquid nitrogen and subsequently
stored at 280uC. Hematoxylin-eosin (HE)-stained sections were
examined for tumor cell types and percentages of cells; tumor
tissues containing more than 80% tumor cells were selected for
further study. The matched normal adjacent tissues were defined
as tissues located at least 1.0, 1.0 and 2.0 cm apart from the
visible tumor lesions in TGCT, TCC and ccRCC, respectively.
Representative histological examination results of the tumors and
matched normal adjacent tissues of TCC, TGCT and ccRCC are
showed in Figure S1.
mRNA and miRNA sequencing and preliminary analyses
of raw data
Total RNA was extracted from normal adjacent tissues and
tumor tissues of each patients studied. Four and five
micrograms of total RNA were subjected to mRNA and
miRNA sequencing library preparation, respectively, before
they were sequenced using the Illumina GAII platform
according to manufacturer’s instructions (Illumina Inc, USA).
Manipulation of raw sequencing data, reference alignment and
determination of differentially expressed mRNA and miRNA
were all performed as described previously [12]. Briefly, the
expression fold change (tumor versus normal) for each gene and
miRNA was calculated as the log2 ratio using the normalized
TPM (transcripts per million reads) values. Subsequently, we
performed a rigorous significance test to determine the
differentially expressed genes and miRNAs [73]. Additionally
considering the large amount of mRNA transcripts, the
resulting P-values (P)w e r ec o r r e c t e df o rm u l t i p l et e s t su s i n g
the FDR (false discovery rate) adjustments [74].
Hierarchical clustering analysis of the mRNA profile
Of the 596 genes that were deregulated in all three cancers, only
64 genes were differentially expressed (absolute value of log2 ratio
$1, FDR #0.01) in at least 75% of 27 patients. The uncentered
correlation was calculated to cluster genes and tumor samples
based on the relative expression of these 64 genes using the
average linkage hierarchical clustering algorithm applied in the
cluster program [75].
Target prediction of differentially expressed miRNAs
We investigated the biological relevance of differentially
expressed miRNAs through their regulation on target genes. First,
a putative target gene set was generated according to the intersect
result of any two predicted algorithms of DIANA-microT 3.0 [76],
TargetScan 5.1 [77], and PicTar [78]. Second, Pearson
correlation analysis was performed using R (http://www.
R-project.org) to determine whether the expression levels of each
miRNA and its mRNA targets were negatively correlated
(P#0.05). Finally, the putative targets confirmed by the correlation
analysis were subjected to further analysis.
KEGG pathway and Gene Ontology analysis of
differentially expressed genes and miRNA targets
Different sets of differentially expressed genes and miRNA
targets were used as input for the DAVID bioinformatics
resource. KEGG pathways with EASE values #0.05 (P-values
from modified Fisher’s exact test; more information can be
found in http://david.abcc.ncifcrf.gov/) were deemed to be
statistically significantly deviated from the expected distribution,
and thus, the corresponding pathways were enriched with the
deregulated genes in question. Considering the large amount
and complex branch structure of GO biological processes, we
used a significance threshold P-value adjusted by Benjamini of
0.05 for biological process terms to control the false discovery
rate [74].
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